Cargando…
Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
BACKGROUND: This study aimed to investigate the safety and feasibility of esophagectomy after neoadjuvant immunotherapy and chemotherapy for esophageal squamous cell carcinoma. METHODS: We retrospectively identified patients who received neoadjuvant immunotherapy combined with chemotherapy (n = 38)...
Autores principales: | Gu, Yi-Min, Shang, Qi-Xin, Zhang, Han-Lu, Yang, Yu-Shang, Wang, Wen-Ping, Yuan, Yong, Hu, Yang, Che, Guo-Wei, Chen, Long-Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195295/ https://www.ncbi.nlm.nih.gov/pubmed/35711710 http://dx.doi.org/10.3389/fsurg.2022.851745 |
Ejemplares similares
-
Editorial: Frontiers' research topic “advances in esophageal cancer surgery with neoadjuvant therapies”
por: Shang, Qi-Xin, et al.
Publicado: (2023) -
Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
por: Ma, Shaohua, et al.
Publicado: (2018) -
Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022) -
Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022) -
The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)